Tanveer Ahmad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tanveer Ahmad has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Lindsay A. Wilson
Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases University College London Queen Square Institute of Neurology London UK
2 shared publications - Venugopalan Yamuna Vishnu
Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
2 shared publications Alisha Reyaz
Department of Neurology, All India Institute of Medical Sciences (AIIMS), Delhi, India
1 shared publication- Alisha Reyaz
Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
1 shared publication - Ashwin Dalal
Diagnostics Division, BRIC-Centre for DNA Fingerprinting and Diagnostics, Hyderabad, Telangana, India
1 shared publication - Asish Vijayaraghavan
Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India
1 shared publication
Latest Publications
- Open Access
- 5 May 2025
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 12 (4) , 513-522
Kennedy's disease from India: An Indian Cohort with multisystemic manifestations
Background: Kennedy's disease (KD) is a rare, insidiously progressive lower motor neuron syndrome characterised by amyotrophy involving the appendicular or bulbar musculature of adult males in their fourth to fifth decade. There are no large series from the Indian subcontinent describing the clinical-genetic and laboratory spectrum of KD. Aim: To describe the clinical, electrophysiologic, metabolic and genetic profile of patients with KD. Methods: We conducted a retrospective review of ten genetically confirmed KD patients. Results: The mean age of the cohort was 47 years, with a mean age of onset of illness at 41.3 ± 9.9 years. The median duration of symptoms before presentation was 5 (3–12) years. The most common referral diagnosis was ALS. The majority presented with symmetric proximal limb weakness with bulbar symptoms and were found to have gynecomastia, lower motor neuron (LMN) facial weakness, and facial and lingual fasciculations. Electrophysiology revealed sensory neuropathy in five patients and chronic neurogenic changes consistent with anterior horn cell disease in all. Metabolic profile showed impaired glycemia, hyperlipidemia and evidence of non-alcoholic fatty liver disease in the majority. All had elevated serum creatine kinase. Genetic testing revealed a median of 46 CAG repeats. The phenotypes of our patients aligned with global data that is predominantly derived from participants of European ancestry. Conclusion: We describe a series of patients with KD from India with significant multisystemic involvement.
- 5 May 2025
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 12 (4) , 513-522
Open AccessKennedy's disease from India: An Indian Cohort with multisystemic manifestations
Background: Kennedy's disease (KD) is a rare, insidiously progressive lower motor neuron syndrome characterised by amyotrophy involving the appendicular or bulbar musculature of adult males in their fourth to fifth decade. There are no large series from the Indian subcontinent describing the clinical-genetic and laboratory spectrum of KD. Aim: To describe the clinical, electrophysiologic, metabolic and genetic profile of patients with KD. Methods: We conducted a retrospective review of ten genetically confirmed KD patients. Results: The mean age of the cohort was 47 years, with a mean age of onset of illness at 41.3 ± 9.9 years. The median duration of symptoms before presentation was 5 (3–12) years. The most common referral diagnosis was ALS. The majority presented with symmetric proximal limb weakness with bulbar symptoms and were found to have gynecomastia, lower motor neuron (LMN) facial weakness, and facial and lingual fasciculations. Electrophysiology revealed sensory neuropathy in five patients and chronic neurogenic changes consistent with anterior horn cell disease in all. Metabolic profile showed impaired glycemia, hyperlipidemia and evidence of non-alcoholic fatty liver disease in the majority. All had elevated serum creatine kinase. Genetic testing revealed a median of 46 CAG repeats. The phenotypes of our patients aligned with global data that is predominantly derived from participants of European ancestry. Conclusion: We describe a series of patients with KD from India with significant multisystemic involvement.
- Open Access
- 25 April 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 32 (9) , 1053-1064
The first genetically confirmed cohort of Facioscapulohumeral Muscular Dystrophy from Northern India
Facioscapulohumeral muscular dystrophy (FSHD) is the third most common form of hereditary myopathy. Sixty per cent of the world’s population lives in Asia, so a significant percentage of the world’s FSHD participants is expected to live there. To date, most FSHD studies have involved individuals of European descent, yet small-scale studies of East-Asian populations suggest that the likelihood of developing FSHD may vary. Here, we present the first genetically confirmed FSHD cohort of Indian ancestry, which suggests a pathogenic FSHD1 allele size distribution intermediate between European and North-East Asian populations and more asymptomatic carriers of 4 unit and 5 unit FSHD1 alleles than observed in European populations. Our data provides important evidence of differences relevant to clinical diagnostics and underscores the need for global FSHD participation in research and trial-ready Indian FSHD cohorts.
- 25 April 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 32 (9) , 1053-1064
Open AccessThe first genetically confirmed cohort of Facioscapulohumeral Muscular Dystrophy from Northern India
Facioscapulohumeral muscular dystrophy (FSHD) is the third most common form of hereditary myopathy. Sixty per cent of the world’s population lives in Asia, so a significant percentage of the world’s FSHD participants is expected to live there. To date, most FSHD studies have involved individuals of European descent, yet small-scale studies of East-Asian populations suggest that the likelihood of developing FSHD may vary. Here, we present the first genetically confirmed FSHD cohort of Indian ancestry, which suggests a pathogenic FSHD1 allele size distribution intermediate between European and North-East Asian populations and more asymptomatic carriers of 4 unit and 5 unit FSHD1 alleles than observed in European populations. Our data provides important evidence of differences relevant to clinical diagnostics and underscores the need for global FSHD participation in research and trial-ready Indian FSHD cohorts.